Leads Biolabs Presents Opamtistomig (PD-L1/4-1BB Bispecific Antibody) to Global Investors at the 2026 Jefferies Global Healthcare Conference
Long-Tail Survival Evidence Points to the Global Potential of IO 2.0
Long-Tail Survival Evidence Points to the Global Potential of IO 2.0
Dual-Target Approach Designed to Modulate Both Innate and Adaptive Immunity Advances Into Clinical Evaluation in
Updated Results Show Deep and Durable Responses in High-Risk, Heavily Pretreated Multiple Myeloma, Supporting Further
Expansion Stage to Compare Opamtistomig Plus Chemotherapy Head-to-Head With Tislelizumab Plus Chemotherapy in
Three Studies Selected for Oral Presentation, Including a Late-Breaking Abstract; Data Highlight Durable Responses and
Extending the Company's Immunologically Cold Tumor Strategy into Colorectal Cancer
Second FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold Tumors
NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,”
NANJING, China, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,”
NANJING, China, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,”
NANJING, China, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,”
NANJING, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,”
